ENTX — Entera Bio Ltd.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1638097 ·
Israel
Last close
$2.74
Market Cap
$475.27M
52W High
$4.20
52W Low
$0.91
ADV30
404,273
Next earnings
2026-11-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | 0 | -4,563,000 | -7,312,000 | 19,480,000 | 11,309,000 | 12,214,000 |
| Mar 2026 | 0 | 0 | -3,539,000 | -3,505,000 | 13,129,000 | 4,137,000 | 2,442,000 |
| Dec 2025 | 0 | 0 | -3,042,000 | -3,016,000 | 15,993,000 | 7,108,000 | 2,892,000 |
| Sep 2025 | 0 | 0 | -3,256,000 | -3,200,000 | 17,407,000 | 8,574,000 | 2,173,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-9,056,000
Investing CF
$-99,000
Financing CF
$503,000
CapEx
$-107,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.26
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-128,871,000
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-12,505,000
Pretax Income TTM
$-12,377,000
Interest Exp TTM
—
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
$-14,369,000
Free Cash Flow
$-6,684,875
Enterprise Value
$480,838,816
Total Cash
$11,309,000
Total Debt
$425,000
Shares Out
173,141,831
Trailing EPS
$-0.35
Book Value
$0.15
ROE
-138.9%
ROA
-46.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 42,000 | -11,529,000 | -11,439,000 | 15,993,000 | 2,892,000 | 13,101,000 | -7,370,000 |
| Dec 2024 | 181,000 | -9,585,000 | -9,541,000 | 9,390,000 | 1,310,000 | 8,080,000 | -6,818,000 |
| Dec 2023 | 0 | -8,891,000 | -8,889,000 | 11,765,000 | 1,379,000 | 10,386,000 | -7,310,000 |
| Dec 2022 | 134,000 | -13,017,000 | -13,071,000 | 13,127,000 | 1,373,000 | 11,754,000 | -12,499,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.55
Max Pain — expiry 2026-11-20 (volume-derived — Yahoo OI feed degraded)
max pain strike: $3.00 · spot: $2.72 · call volume: 169 · put volume: 130
Expected Move to 2026-11-20:
±$2.20
(80.73%) —
implied range
$0.52 –
$4.92
· ATM straddle on $3.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TECX | Tectonic Therapeutic, Inc. | $462.73M | $23.67 | — |
| RGNX | REGENXBIO Inc. | $488.50M | $7.40 | — |
| AUTL | Autolus Therapeutics plc | $493.73M | $1.86 | — |
| AGMB | AgomAb Therapeutics NV | $517.60M | $10.51 | — |
| PRME | Prime Medicine, Inc. | $525.99M | $2.90 | — |
News headlines (Yahoo Finance, 1h cache)
Entera to Participate in Upcoming Fall Investor Conferences
2026-08-27 12:00 · Yahoo
Entera Bio shares slip as Q2 loss comes in wider than expected
2026-08-10 11:02 · Yahoo
Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
2026-07-31 20:30 · Yahoo
Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement
2026-07-27 12:30 · Yahoo
ENTX Stock On Track For Best Day In Over 5 Years — What’s Driving The Rally?
2026-06-22 18:29 · Yahoo
Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
2026-06-16 12:33 · Yahoo
Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline
2026-05-28 12:50 · Yahoo
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
2026-05-08 20:05 · Yahoo
Correction: Entera to Participate in Upcoming Fall Investor Conferences
2026-08-27 13:44 · Yahoo
Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation
2026-08-18 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.